LLY

Eli Lilly & Co
D

LLY

Arincen80/100B

Eli Lilly & Co executives and insider trading

David A. Ricks reported no open-market purchases or sales over the last twelve months.

Over the last twelve months Eli Lilly & Co's insiders sold 36,828 shares for 41.60M USD in 7 sales on the open market, and bought 0 shares in 0 purchases.

Insiders over the last twelve months

Insider sales
7
Shares sold
36,828
Value sold
41.60M USD
Insider purchases
0

Insiders buying against selling

Bought on the market
Sold on the market
0
1 week
0
0
1 month
7.01M USD
0
3 months
14.65M USD
0
6 months
25.85M USD
0
1 year
41.60M USD
4.54M USD
2 years
2.76B USD
Sold, decided at the timeSold under a Rule 10b5-1 plan set in advance

Open-market purchases and sales reported on Form 4, by value. Awards, option exercises and shares withheld for tax are not counted. Whether a sale was under a Rule 10b5-1 plan is read from each Form 4 at the SEC (the box exists on filings since April 2023).

Executives and directors

The people who run the company and the directors who reported trades, with what each bought and sold on the open market over the last twelve months. The CEO first, then whoever traded most.

NamePositionAgeShares sold (12 months)Value sold (12 months)Shares bought (12 months)Last saleShares held after
Endowment Inc Lilly Other: Former 10% Shareholder—15,82815.75M USD—6 May 202691,883,358
Anat Hakim Executive Vice President, General Counsel & Secretary5710,00012.96M USD—2 Nov 20264,137
Patrik Jonsson Executive VP & President of Lilly International596,5007.64M USD—17 Aug 202653,443
Ilya Yuffa Executive VP and President of Lilly USA & Global Customer Capabilities512,5002.88M USD—10 Jun 202629,804
Donald A. Zakrowski Senior Vice President of Finance & Chief Accounting Officer—2,0002.37M USD—10 Aug 20261,526

Insider sales and purchases by quarter

How many insider sales and purchases were reported each quarter.

Insider sales Insider purchases

Every insider transaction

Insiders must report every trade in the company's shares to the SEC within two business days, on Form 4. Only purchases and sales are trades on the open market; awards, option exercises, shares withheld for tax and gifts come with pay, and the twelve-month totals leave them out.

DateNameTransactionSharesPriceValueShares held afterFiling
2 Nov 2026Anat HakimSale5,0001,402.527.01M USD4,137Form 4
17 Aug 2026Patrik JonssonSale6,5001,175.107.64M USD54,147Form 4
10 Aug 2026Donald A. ZakrowskiSale2,0001,185.012.37M USD1,526Form 4
7 Aug 2026Anat HakimSale5,0001,190.005.95M USD11,875Form 4
10 Jun 2026Ilya YuffaSale2,5001,150.772.88M USD29,804Form 4
6 May 2026Endowment Inc LillySale13,620995.2313.55M USD91,883,358Form 4
6 May 2026Endowment Inc LillySale2,208996.182.20M USD91,881,150Form 4
19 Sept 2025Endowment Inc LillySale22,965763.0517.52M USD95,607,387Form 4
19 Sept 2025Endowment Inc LillySale700764.47535.13K USD95,606,687Form 4
18 Sept 2025Endowment Inc LillySale39,863763.2930.43M USD95,697,115Form 4
18 Sept 2025Endowment Inc LillySale23,067764.5217.64M USD95,674,048Form 4
18 Sept 2025Endowment Inc LillySale26,647765.5720.40M USD95,647,401Form 4
18 Sept 2025Endowment Inc LillySale13,135766.4510.07M USD95,634,266Form 4
18 Sept 2025Endowment Inc LillySale3,914767.073.00M USD95,630,352Form 4
28 Aug 2025Donald A. ZakrowskiSale1,000734.93734.93K USD3,840Form 4

Common questions about Eli Lilly & Co's executives and insiders

Source: Financial Modeling Prep